Seeking Alpha

Merck buys Idenix

  • In an all-cash deal, Merck (MRK) acquires Hep C drug maker Idenix Pharmaceuticals (IDIX) for $24.50/share ($3.85B). The company has an attractive portfolio of Hep C product candidates based on nucleotide/nucleoside chemistry and prodrug technologies.
From other sites
Comments (19)
  • Patent News
    , contributor
    Comments (1454) | Send Message
     
    wow. baupost making a huge payday
    9 Jun 2014, 08:05 AM Reply Like
  • Patent News
    , contributor
    Comments (1454) | Send Message
     
    that means seth klarman makes about a billion$ minus cost of their shares at about 2.5 or 3
    9 Jun 2014, 08:06 AM Reply Like
  • SWIMMER
    , contributor
    Comments (14) | Send Message
     
    Sounds like a lot of money for someone coming late to the game. Differentiation may become interesting
    9 Jun 2014, 08:08 AM Reply Like
  • the_value_vulture
    , contributor
    Comments (245) | Send Message
     
    ...and I sold 30% of my position on Friday to shore up a higher cash position.
    9 Jun 2014, 08:13 AM Reply Like
  • Patent News
    , contributor
    Comments (1454) | Send Message
     
    wow bad timing
    9 Jun 2014, 08:16 AM Reply Like
  • Unconventional Capital Wisdom
    , contributor
    Comments (266) | Send Message
     
    Another example of patience beening rewarded
    9 Jun 2014, 09:02 AM Reply Like
  • Implied Value
    , contributor
    Comments (119) | Send Message
     
    Great call(s) on IDIX. Never bet against Klarman.
    9 Jun 2014, 10:36 AM Reply Like
  • Unconventional Capital Wisdom
    , contributor
    Comments (266) | Send Message
     
    Thanks IV
    9 Jun 2014, 06:06 PM Reply Like
  • bhtaylor29
    , contributor
    Comments (88) | Send Message
     
    So who is next up? Im putting down money that its HALO or JAZZ. HALO for the patent cliff mix of current drugs it enhances, and JAZZ offers excellent tax advantages for any company buying it due to its HQ being in Ireland.
    9 Jun 2014, 09:38 AM Reply Like
  • CMPMD
    , contributor
    Comments (177) | Send Message
     
    Gilead feeling some pressure due to this.
    9 Jun 2014, 09:40 AM Reply Like
  • Menicholas
    , contributor
    Comments (1171) | Send Message
     
    Anyone know when the deal will be finalized? Trying to decide whether to take the money and run now or wait for the buyout to go through.
    9 Jun 2014, 09:45 AM Reply Like
  • dheuring
    , contributor
    Comments (9) | Send Message
     
    Don't be greedy. Take the money.
    9 Jun 2014, 10:09 AM Reply Like
  • Welt
    , contributor
    Comments (216) | Send Message
     
    TAKE THE MONEY
    9 Jun 2014, 12:20 PM Reply Like
  • newnnly
    , contributor
    Comments (261) | Send Message
     
    agree. take the money
    9 Jun 2014, 05:56 PM Reply Like
  • Menicholas
    , contributor
    Comments (1171) | Send Message
     
    I almost sold some on Friday.
    9 Jun 2014, 09:45 AM Reply Like
  • Kishavan
    , contributor
    Comments (106) | Send Message
     
    Thank you Seth Klarman.
    9 Jun 2014, 10:19 AM Reply Like
  • T-time
    , contributor
    Comments (672) | Send Message
     
    The winner here is the opportunity to buy GILD under 80 - probably LAST chance!
    9 Jun 2014, 10:44 AM Reply Like
  • Jimghad
    , contributor
    Comments (340) | Send Message
     
    Merck Gilead and Abbvie are in the race.
    Wonder what Janssen is up to.
    They are a big Co. They are not going to roll over and play dead.
    9 Jun 2014, 03:42 PM Reply Like
  • hessmessinc
    , contributor
    Comments (19) | Send Message
     
    Opportunity continues to buy $ONCS...
    10 Jun 2014, 12:38 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs